Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swiss TAVR firm attracts SwFr23m funding

This article was originally published in Clinica

Executive Summary

Symetis, a Swiss company developing a transcatheter aortic valve replacement (TAVR) system, has attracted SwFr23m ($21.2m) in equity financing. The investment round was co-led by Wellington Partners and Vinci Capital-Renaissance PME, and included the participation of new investor Banexi Venture Partners and Symetis’ existing shareholders. The funds will be used to advance the clinical development of Symetis’ Acurate TA self-positioning TAVR system. The Lausanne-based firm is expecting to initiate its first-in-man study in the second half of 2009 and begin testing and validation of Acurate TF, a transfemoral version of the technology.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel